|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...4546474849505152535455...110111» |
- | Trial completion, Surgery: Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus (clinicaltrials.gov) - May 28, 2015
P3, N=2616, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment change: Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - May 28, 2015
P=N/A, N=36, Completed, Sponsor: University of California, San Diego
Active, not recruiting --> Completed N=50 --> 36
- dexamethasone / Generic mfg.
Enrollment open: dexFEM: Dexamethasone for Excessive Menstruation (clinicaltrials.gov) - May 28, 2015
P2, N=128, Recruiting, Sponsor: University of Edinburgh
N=50 --> 36 Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: Prevention of HPV in the School Health Service (clinicaltrials.gov) - May 28, 2015
P=N/A, N=1050, Active, not recruiting, Sponsor: Uppsala University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Mar 2016
- Sancuso (granisetron) / Solasia
Trial completion, Enrollment change, Trial primary completion date: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - May 28, 2015
P=N/A, N=4, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Mar 2016 Suspended --> Completed | N=60 --> 4 | Trial primary completion date: Jan 2012 --> Mar 2013
- cisplatin / Generic mfg., pemetrexed / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy, Metastases: Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer (clinicaltrials.gov) - May 28, 2015
P2, N=55, Completed, Sponsor: Gynecologic Oncology Group
Suspended --> Completed | N=60 --> 4 | Trial primary completion date: Jan 2012 --> Mar 2013 Recruiting --> Completed | Trial primary completion date: Sep 2010 --> Jul 2014
- | Biomarker, Trial completion: Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer (clinicaltrials.gov) - May 28, 2015
P=N/A, N=684, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | Trial primary completion date: Sep 2010 --> Jul 2014 Active, not recruiting --> Completed
- | Trial completion: Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva (clinicaltrials.gov) - May 28, 2015
P3, N=515, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Gralise (gabapentin) / Alvogen
Enrollment change: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - May 27, 2015
P=N/A, N=250, Recruiting, Sponsor: University of Tennessee
Active, not recruiting --> Completed N=120 --> 250
- New trial: Follow-up of Ovarian Function in Young Women Who Underwent Ovarian Cortex Cryopreservation (clinicaltrials.gov) - May 27, 2015
P=N/A, N=546, Enrolling by invitation, Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open, Phase classification, Enrollment change, Trial primary completion date: The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes (clinicaltrials.gov) - May 27, 2015
P=N/A, N=800, Recruiting, Sponsor: Antalya IVF
N=120 --> 250 Terminated --> Recruiting | Phase classification: P4 --> PN/A | N=400 --> 800 | Trial primary completion date: Mar 2015 --> Jun 2016
- ||| Enrollment closed, Trial primary completion date: Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis (clinicaltrials.gov) - May 27, 2015
P1/2, N=188, Active, not recruiting, Sponsor: NovaDigm Therapeutics, Inc.
Terminated --> Recruiting | Phase classification: P4 --> PN/A | N=400 --> 800 | Trial primary completion date: Mar 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015
- Trial completion, Enrollment change, Trial primary completion date: TG-Adnex: Feasability Study of Removing the Ovaries and Fallopian Tubes (clinicaltrials.gov) - May 27, 2015
P=N/A, N=6, Completed, Sponsor: Heidelberg University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015 Not yet recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Mar 2013 --> Dec 2014
- Trial completion, Trial primary completion date: Implementation of an Efficacious Intervention for High Risk Women in Mexico (clinicaltrials.gov) - May 27, 2015
P=N/A, N=1228, Completed, Sponsor: University of California, San Diego
Not yet recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Mar 2013 --> Dec 2014 Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Apr 2015
- | Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Trial completion: Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting (clinicaltrials.gov) - May 27, 2015
P4, N=20, Completed, Sponsor: Gynecologic Oncology Associates
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Apr 2015 Terminated --> Completed
- Trial completion: Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico (clinicaltrials.gov) - May 27, 2015
P=N/A, N=400, Completed, Sponsor: University of California, San Diego
Terminated --> Completed Active, not recruiting --> Completed
- || New P3 trial: A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime (clinicaltrials.gov) - May 27, 2015
P3, N=88, Recruiting, Sponsor: Gema Biotech S.A.
- New P2 trial: Biobehavioral Intervention in Gynecologic Oncology Patients (clinicaltrials.gov) - May 27, 2015
P2, N=30, Not yet recruiting, Sponsor: Rachel Miller
- dasatinib / Generic mfg.
Enrollment closed, Trial primary completion date: Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer (clinicaltrials.gov) - May 27, 2015
P0, N=20, Active, not recruiting, Sponsor: University of Virginia
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015
- |||| Cvac (cancer vaccine MUC-1) / Sydys Corp
Trial completion: Ovarian Cancer Vaccine for Patients in Remission (clinicaltrials.gov) - May 27, 2015
P2b, N=63, Completed, Sponsor: Prima BioMed Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> May 2015 Active, not recruiting --> Completed
- azithromycin / Generic mfg.
Trial completion: C/SOAP: Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection (clinicaltrials.gov) - May 26, 2015
P=N/A, N=2013, Completed, Sponsor: Alan Tita
Active, not recruiting --> Completed Recruiting --> Completed
- SG 2000 / AstraZeneca
Enrollment change: SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin (clinicaltrials.gov) - May 26, 2015
P2, N=19, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=50 --> 19
- ||| New trial: C (clinicaltrials.gov) - May 22, 2015
P=N/A, N=1200, Recruiting, Sponsor: University of Aarhus
- ||| Trial completion, Enrollment change: CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening (clinicaltrials.gov) - May 22, 2015
P=N/A, N=1570, Completed, Sponsor: OHSU Knight Cancer Institute
N=50 --> 19 Active, not recruiting --> Completed | N=400 --> 1570
- ropivacaine / Generic mfg.
New trial, Surgery: Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery (clinicaltrials.gov) - May 21, 2015
P=N/A, N=60, Recruiting, Sponsor: Ewha Womans University Mokdong Hospital
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: TNFSF11 Inhibition and Fertility: a Prospective Study (clinicaltrials.gov) - May 21, 2015
P2, N=15, Recruiting, Sponsor: Martin Blomberg Jensen
Active, not recruiting --> Completed | N=400 --> 1570 Not yet recruiting --> Recruiting
- DCVAC/OvCa / Sotio
Enrollment closed: SOV02: Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma (clinicaltrials.gov) - May 21, 2015
P2, N=60, Active, not recruiting, Sponsor: Sotio a.s.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| veliparib (ABT-888) / AbbVie
Enrollment closed, BRCA Biomarker: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status (clinicaltrials.gov) - May 21, 2015
P1/2, N=80, Active, not recruiting, Sponsor: Vejle Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | veliparib (ABT-888) / AbbVie
Enrollment closed, Enrollment change, Monotherapy, BRCA Biomarker, PARP Biomarker: Veli-BRCA: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (clinicaltrials.gov) - May 21, 2015
P1/2, N=49, Active, not recruiting, Sponsor: Vejle Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=33 --> 49
- Preclinical, Enrollment change, Trial withdrawal, Trial primary completion date: Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine (clinicaltrials.gov) - May 20, 2015
P2, N=0, Withdrawn, Sponsor: Sykehuset Telemark
Recruiting --> Active, not recruiting | N=33 --> 49 N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2011 --> Jan 2014
- New trial: LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation (clinicaltrials.gov) - May 20, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: Rambam Health Care Campus
- | New P1/2 trial: TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (clinicaltrials.gov) - May 20, 2015
P1/2, N=50, Completed, Sponsor: TherapeuticsMD
- DCVAC/OvCa / Sotio
Enrollment closed, Trial primary completion date: Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma (clinicaltrials.gov) - May 20, 2015
P2, N=60, Active, not recruiting, Sponsor: Sotio a.s.
N=150 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2011 --> Jan 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Jan 2017
- Trial completion: High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - May 19, 2015
P=N/A, N=31, Completed, Sponsor: Norwegian University of Science and Technology
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Jan 2017 Active, not recruiting --> Completed
- Elonva (corifollitropin alfa) / Organon
New P1 trial: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study (clinicaltrials.gov) - May 19, 2015
P1, N=40, Enrolling by invitation, Sponsor: University of Sao Paulo
- ||| Enrollment open, BRCA Biomarker, IO biomarker: ENGAGE: Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer (clinicaltrials.gov) - May 19, 2015
P=N/A, N=800, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: TORCH: Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4 (clinicaltrials.gov) - May 19, 2015
P=N/A, N=250, Recruiting, Sponsor: Centre Hospitalier Departemental Vendee
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - May 17, 2015
P3, N=659, Completed, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| New trial: Dual Rapid HIV & Syphilis Tests in Zambia (clinicaltrials.gov) - May 15, 2015
P=N/A, N=3765, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- New trial: The Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome (clinicaltrials.gov) - May 15, 2015
P=N/A, N=900, Recruiting, Sponsor: McGill University Health Center
- ||||| etonogestrel/ethinylestradiol intravaginal ring / Generic mfg.
New P4 trial: Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity (clinicaltrials.gov) - May 15, 2015
P4, N=120, Not yet recruiting, Sponsor: University of Washington
- New trial: Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients (clinicaltrials.gov) - May 14, 2015
P=N/A, N=120, Recruiting, Sponsor: University of Michigan
- ||||| nystatin oral / Generic mfg.
New P4 trial: Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis (clinicaltrials.gov) - May 14, 2015
P4, N=169, Completed, Sponsor: Innotech International
- Impracor (ketoprofen) / Harrow Health
Enrollment open, Trial primary completion date: Novel Topical Therapies for the Treatment of Genital Pain (clinicaltrials.gov) - May 14, 2015
P2/3, N=30, Enrolling by invitation, Sponsor: University of Rochester
Active, not recruiting --> Completed Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment closed, Trial primary completion date: Frozen Embryo Donation Study (clinicaltrials.gov) - May 14, 2015
P=N/A, N=1200, Active, not recruiting, Sponsor: Boston IVF
Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2014 --> Dec 2015 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Aug 2013 --> Aug 2014
- ||| Trial completion, Trial primary completion date: Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS) (clinicaltrials.gov) - May 14, 2015
P=N/A, N=86, Completed, Sponsor: Milton S. Hershey Medical Center
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Aug 2013 --> Aug 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014
- | cabergoline / Generic mfg.
Trial completion: Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (clinicaltrials.gov) - May 12, 2015
P2/3, N=200, Completed, Sponsor: Benha University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2014 Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment change: Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (clinicaltrials.gov) - May 12, 2015
P2, N=70, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=55 --> 70
- ||||||| Avastin (bevacizumab) / Roche
Trial completion: A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer (clinicaltrials.gov) - May 12, 2015
P3, N=1041, Completed, Sponsor: Hoffmann-La Roche
N=55 --> 70 Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion, Enrollment change: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - May 12, 2015
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=50 --> 37